证券代码：688621 证券简称：阳光诺和 公告编号：2024-021 协议转让计划终止的主要内容 公司于近日收到股东刘宇晶先生出具的《股份转让计划终止告知函》。截至 目前，刘宇晶先生于 2024 年 3 月 16 日披露的《北京阳光诺和药物研究股份有限 公司关于持股 5%以上股东增加一致行动人及一致行动人之间内部转让股份计划 的提示性公告》（以下简称"转让计划"），股东未进行股份转让，现决定终止该转 让计划。 减持计划的主要内容 因股东自身资金需求刘宇晶先生拟通过大宗交易方式减持，合计不超过 1,516,795 股，即不超过公司总股本的 1.35%。通过大宗交易方式减持的，自本公 告披露之日起 3 个交易日之后的 3 个月内进行。 北京阳光诺和药物研究股份有限公司 股东、董监高终止协议转让计划暨减持股份计划 的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持股的基本情况 截至本报告披露日，刘宇晶先生直接持有公司股份 6,067,181 股，占公司总 股本的 5.42%。以 ...

各位投资者参加我们华安医药联合录影中举办的夏季线上策略会我是华安医药谈国超团队的医药研究员杨复元那我们今天本场呢是上市公司阳光诺和的交流我们也是非常荣幸的邀请到了公司领导董秘赵总还有证券事务代表魏总来和我们一起交流那我们今天的这个交流呢也是分为公司介绍还有投资者问答两个部分 那我们首先先有请公司领导用一些时间然后来对公司的这个经营情况还有最新进展来帮我们做一个简单的更新吧那有请魏总好的好的谢谢那 各位投资者上午好首先欢迎各位参加阳光洞河的业绩说明然后我先给大家来介绍一下公司2023年和2024年一季度的相关的业绩情况 公司2023年实现总营业收入9.32亿同比增长了37.76%然后归属于母公司净利润1.85亿元同比增长18.08% 其中呢2023年毛利率阳光度和整体的这个毛利率在56.68%同比增长1.19个百分点净利润呢公司净资产收益率达到了19.22%同比增长0.27个百分点 公司2023年基本每股收益呢在1.65元每股同比增长17.86%人均人均产值呢在77.69万元同比增长17.60% 2024年一季度财务数据公司营业收入公司2024年第一季度营业收入为2.52亿元然后同比增长8.53%归属于母公司净 ...

各位投资者参加我们华安医药联合录影中举办的夏季线上策略会我是华安医药谈国超团队的医药研究员杨复元我们今天本场是上市公司阳光诺禾的交流我们也是非常荣幸的邀请到了公司领导董秘赵总还有根据事务代表魏总来和我们一起交流我们今天的交流也是分为公司介绍还有投资者问答两个部分 那我们首先先有请公司领导用一些时间然后来对公司的这个经营情况还有最新进展来帮我们做一个简单的更新吧那有请魏总好的好的谢谢那各位投资者上午好那个首先欢迎各位参加阳光络合的这个业绩说明 然后我先给大家来介绍一下公司2023年和2024年一季度的相关的业绩情况公司2023年实现总营业收入9.32亿同比增长了37.76%然后归属于母公司净利润1.85亿元同比增长18.08% 其中2023年毛利率阳光度和整体的毛利率在56.68%同比增长1.19个百分点净利润公司净资产收益率达到了19.22%同比增长0.27个百分点 公司2023年基本每股收益在1.65元每股同比增长17.86%人均产值在77.69万元同比增长17.60%2024年一季度财务数据公司营业收入公司2024年第一季度营业收入为2.52亿元 然后同比增长8.53%归属于母公司净利润为7275.38万 ...

京天股字（2024）第 211 号 致：北京阳光诺和药物研究股份有限公司 北京阳光诺和药物研究股份有限公司（以下简称公司）2023 年年度股东大会 （以下简称本次股东大会）采取现场投票与网络投票相结合的方式，现场会议于 2024 年 5 月 16 日（周四）15:30 在北京市昌平区科技园区双营西路 79 号院 29 号 楼公司会议室召开。北京市天元律师事务所（以下简称本所）接受公司聘任，指派 本所律师现场参加本次股东大会现场会议，并根据《中华人民共和国公司法》《中 华人民共和国证券法》（以下简称《证券法》）《上市公司股东大会规则》（以下 简称《股东大会规则》）以及《北京阳光诺和药物研究股份有限公司章程》（以下 简称《公司章程》）等有关规定，就本次股东大会的召集、召开程序、出席现场会 议人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《北京阳光诺和药物研究股份有限公司第 二届董事会第十次会议决议公告》《北京阳光诺和药物研究股份有限公司第二届监 事会第九次会议决议公告》《北京阳光诺和药物研究股份有限公司关于召开 2023 年年度股东大会的通知》（以下简称《召 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2024-020 北京阳光诺和药物研究股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 5 月 16 日 （二） 股东大会召开的地点：北京市昌平区科技园区双营西路 79 号院 29 号楼 公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 15 | | --- | --- | | 普通股股东人数 | 15 | | 2、出席会议的股东所持有的表决权数量 | 45,120,396 | | 普通股股东所持有表决权数量 | 45,120,396 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 40.2861 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 40.2861 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][4]. Core Views - The company achieved a revenue of 930 million yuan in 2023, representing a year-on-year growth of 37.76%, and a net profit attributable to shareholders of 180 million yuan, up 18.08% year-on-year [2]. - The company signed new orders worth 1.504 billion yuan in 2023, a 36.50% increase year-on-year, indicating a strong order intake despite some challenges in customer payments [2]. - The company is actively expanding its business areas, with significant growth in its pharmaceutical research services and clinical trial services, achieving revenues of 570 million yuan and 360 million yuan respectively in 2023 [2]. - The company has increased its R&D investment, with R&D expenses reaching 120 million yuan in 2023, a 37.91% increase year-on-year, and has made progress in its self-developed drug pipeline [2]. Financial Summary - The company forecasts net profits of 259 million yuan, 357 million yuan, and 482 million yuan for 2024, 2025, and 2026 respectively, with corresponding growth rates of 40.4%, 37.7%, and 35.0% [2][14]. - The current price-to-earnings (P/E) ratios are projected to be 23X, 17X, and 12X for the years 2024, 2025, and 2026 respectively [2][14]. - The company reported a net profit margin of 19.8% in 2023, with expectations for gradual improvement in the coming years [14].

Investment Rating - The report assigns a "Buy" rating for the company, with expected net profits of 268 million, 356 million, and 455 million for 2024, 2025, and 2026 respectively, corresponding to current market valuations of 24, 18, and 14 times [4][38]. Core Insights - The company reported a revenue of 932 million yuan for 2023, representing a year-on-year growth of 37.76%. The net profit attributable to the parent company was 185 million yuan, up 18.08%, while the net profit excluding non-recurring items was 180 million yuan, reflecting a growth of 26.67%. In Q1 2024, revenue reached 252 million yuan, a growth of 8.53%, with a net profit of 72.75 million yuan, up 51.77% [34][38]. - The company has maintained a high growth rate in new orders, with a total of 1.504 billion yuan in new contracts signed in 2023, a growth rate of 36.50%, and a cumulative order backlog of 2.566 billion yuan, up 28.69% [20][37]. - The company has a robust R&D investment strategy, with R&D expenses reaching 124 million yuan in 2023, a year-on-year increase of 37.91%, accounting for 13.27% of total revenue. The company has initiated over 100 new R&D projects in 2023, totaling more than 350 projects [27][37]. Financial Summary - For 2023, the company achieved total revenue of 932 million yuan, with a gross profit of 528 million yuan, resulting in a gross margin of 57%. The operating profit was 194 million yuan, with a net profit of 185 million yuan [9][34]. - The company expects to continue its growth trajectory, projecting revenues of 1.249 billion, 1.583 billion, and 1.979 billion yuan for 2024, 2025, and 2026 respectively [9][34]. - The company has a strong cash flow position, with net cash flow from operating activities of 93 million yuan in 2023, and projected increases in subsequent years [9][34].

Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Views - The company has achieved significant revenue growth, with 2023 revenue reaching 930 million (up 37.8%) and a net profit of 180 million (up 18.1%) [2][3]. - The company has established a comprehensive "preclinical + clinical" drug development service platform, enhancing its competitive advantage and customer retention [4]. - The company has a robust order backlog of 2.57 billion (up 28.7% year-on-year), indicating strong future revenue potential [2][3]. Financial Performance - In Q1 2024, the company reported revenue of 250 million (up 8.5%) and a net profit of 72.75 million (up 51.8%) [2][3]. - The company achieved a per capita output value of 747,000 (up 14.6% year-on-year) in 2023 [3]. - The company has initiated over 100 new self-research projects in 2023, bringing the total to over 350 projects [3]. Profit Forecast - Revenue growth rates are projected at 32.63%, 31.66%, and 30.61% for 2024, 2025, and 2026, respectively [4]. - Net profit growth rates are expected to be 39.10%, 36.71%, and 34.92% for the same years [4]. - Earnings per share (EPS) are forecasted to be 2.29, 3.14, and 4.23 yuan per share for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 24.34, 17.80, and 13.20 [4].

Group 1: Business Overview - Sunshine Nuohua has gradually entered the clinical CRO business since 2016, with revenue increasing annually, although operating costs and gross margins remain lower than those of pharmaceutical research services [3][4]. - The company aims to diversify its business and enhance its competitive edge by expanding into the clinical CRO sector, which is crucial for the pharmaceutical R&D process [3][4]. Group 2: Market Potential and Strategy - The long-term consideration for entering the clinical CRO field is based on the market outlook and growth potential, as the demand for clinical CRO services is steadily increasing with the development of the domestic pharmaceutical market [3][4]. - The company plans to focus its resources on meeting domestic needs for clinical research services in both generic and innovative drugs, integrating preclinical and clinical research strategies for horizontal expansion [7][8]. Group 3: Financial Performance - In 2023, the company achieved a new order amount of CNY 1.504 billion, with a growth rate of 36.50%, and a cumulative order backlog of CNY 2.566 billion, reflecting a year-on-year increase of 28.69% [10][11]. - R&D investment in 2023 reached CNY 124 million, a year-on-year increase of 37.91%, accounting for 13.27% of revenue, indicating a commitment to maintaining technological leadership and competitiveness [11][12]. Group 4: Research and Development Focus - The company has over 350 self-initiated R&D projects, including innovative drugs, modified new drugs, and generic drugs, with a focus on pain relief, kidney disease, oncology, and other therapeutic areas [8][9]. - Sunshine Nuohua is expanding its R&D capabilities in special formulations, including peptide drugs, pediatric medications, and transdermal delivery systems, to meet diverse market demands [10][12]. Group 5: Future Outlook - The domestic CRO industry is expected to continue its growth trajectory, with increasing recognition from pharmaceutical companies and a steady rise in drug registration applications [6][7]. - The company is committed to enhancing its R&D team and capabilities to address the growing market needs and challenges in various disease areas [12].

Group 1: Business Overview - Sunshine Nuohuo has gradually entered the clinical CRO business since 2016, with revenue increasing annually, although operating costs and gross margins remain lower than those of pharmaceutical research services [3][4]. - The company aims to diversify its business and enhance competitiveness by expanding into the clinical CRO sector, which is seen as a critical part of the pharmaceutical R&D process [3][4]. Group 2: Financial Performance - In 2023, the company achieved a new order amount of CNY 1.504 billion, representing a growth rate of 36.50%, with cumulative orders reaching CNY 2.566 billion, a year-on-year increase of 28.69% [10][11]. - R&D investment in 2023 was CNY 124 million, a year-on-year increase of 37.91%, accounting for 13.27% of revenue [11][12]. Group 3: Market Strategy - The company is focusing on meeting domestic demands for clinical research services in both generic and innovative drugs, integrating preclinical and clinical research strategies for horizontal expansion [7][8]. - Sunshine Nuohuo plans to enhance its R&D pipeline by increasing self-initiated projects, particularly in innovative drugs, improved new drugs, and specialty generics [11][12]. Group 4: Product Development - The company has over 350 self-initiated projects, including innovative drugs, improved new drugs, and generics, with a focus on pain relief, kidney disease, oncology, and other therapeutic areas [9][10]. - Sunshine Nuohuo has established a comprehensive platform for special formulations, including peptide drugs, pediatric medications, and transdermal delivery systems [10][12]. Group 5: Future Outlook - The domestic CRO industry is expected to continue growing, with increasing recognition from pharmaceutical companies and a steady rise in drug registration applications [6][7]. - The company is committed to expanding its R&D team and capabilities to meet the growing market demands across various therapeutic areas [12].